Can you trust comments online? Not always, according to the Washington Post, which revealed that among 1,400 comments on proposed cuts to a drug discount program many comments were duplicates or exact copies. A panel examined biosimilars and listened to the public's questions and concerns, and in
Many Steps Taken to Lower the Cost of Prescription Drugs
Value-based drug pricing, looser restrictions on Part D drug formularies...it seems as if every group and organization is trying to help patients access and pay for their medications. In this week’s Innovation Partners BioBlog, we’ll take a look at oncology biosimilars, Medicaid value-based drug
The Deal Goes Through – A Look at the Cigna, ExpressScripts Purchase of PBM and More
This week’s Innovation Partners BioBlog takes a look at several aspects of the business of healthcare. First, the impressive news that the Cigna, Express Scripts deal to acquire PBM was approved by shareholders in both companies, a move that goes against expert predictions. Over 150 medical
Are Prescription Drug Prices Changing – for the Better?
The news this week is mixed on whether or not the Trump Administration’s push to lower the cost of prescription drugs is working. CVS is launching their own program to target expensive new drugs, while the US Health Secretary repeats the desire to eliminate drug rebates. Anthem is taking steps to
The Costs of Prescription Drugs
This week’s Innovation Partners BioBlog looks at costs - the cost of prescription drugs. From CVS shifting drug pricing leverage to new data showing hidden costs in Medicare’s prescription drug program, the cost of medication is definitely in the spotlight right now. CVS' move to lean on ICER
Bundled Payments Reduce Referrals to SNFs, FDA Warning about the Use of Antibiotics after Donor Stem Cell Transplant, More
This week's BioBlog looks at the world of pharmaceuticals and the changes, updates, and news that shape the industry. The FDA issued a warning on the use of azithromycin after donor stem cell transplant this week. Hospitals are reducing their referrals to skilled nursing facilities if they switch to
Advances in the Fight Against Cancer, Drug Prices and More
This week the FDA approved a new treatment for rare adrenal gland tumors. Researchers at Johns Hopkins made a discovery that could lead to breakthroughs in the fight against cancer, and drug companies are talking openly about drug prices. These top stories and more in this week’s Innovation Partners
Soaring Drug Prices Under Continuing Scrutiny
Soaring drug prices continue to be under scrutiny this week as our lead story attests. CAR-T therapy offers hope to cancer patients but at what cost to insurers? The Trump Administration continues its offensive against big pharma and drug price increases. These top stories and more in this week’s